CDISC is an open, multidisciplinary, non-profit organization committed to the development of industry standards to support the electronic acquisition, exchange, submission and archiving of clinical trials data and metadata for medical and biopharmaceutical product development. The mission of CDISC is to lead the development of global, vendor-neutral, platform independent standards to improve data quality and accelerate product development in our industry.
HL7 is a standards development organization dealing with data standards for all health care operations; CDISC is oriented to biopharmaceutical drug development only. Because of HL7's broader scope it hasn't dealt much with the nuances of clinical trials, while CDISC hasn't dealt with health care applications important to HL7 such as reimbursements and order processing. Meanwhile, the clinical drug research industry in general has not participated historically in HL7, viewing it as a different industry and application. The differences are the industry, user community, and different standards, as CDISC deals only with clinical trials or regulatory submissions..." [from the Mission Statement and FAQ document]
XML schemas and/or DTDs are provided, for example, in connection with the Operational Data Model (ODM) Final Version 1.2, the CDISC LAB Base Model Version 1.0.1, and the Microbiology Extension for the LAB Base Model.
An announcement of 2000-11-28 from the Clinical Data Interchange Standards Consortium (CDISC) describes the completed development of FDA safety domain metadata models and an XML DTD for clinical data interchange. The XML DTD and associated documentation from the CDISC Operational Data Modeling Group are available for download. The announcement says, in part: "The Clinical Data Interchange Standards Consortium has achieved two significant milestones towards its goal of standard data models to streamline drug development and regulatory review processes. CDISC participants have completed metadata models for the 12 safety domains listed in the FDA Guidance regarding Electronic Submissions and have produced a revised XML-based data model to support data acquisition and archive. The Submissions Data Standards team has been working since early 1999 to define a metadata model that is designed to: (1) provide regulatory submission reviewers with clear descriptions of the usage, structure, contents and attributes of all submitted datasets and variables; (2) allow reviewers to replicate analyses, tables, graphs and listings with minimal or no transformations; (3) enable reviewers to easily view and subset the data used to generate any analysis, table, graph or listing without complex programming. This team, under the leadership of Wayne Kubick of Lincoln Technologies, and Dave Christiansen of Genentech, presented their metadata models to a group of representatives at the FDA on October 10 and discussed future cooperative efforts with Agency reviewers. The CDISC Operational Data Modeling (ODM) Working Group released their Version 1.0 model for data acquisition, interchange and archive. A small, interdisciplinary team was formed in September of 1999 to examine two different XML-based data interchange models (which had been separately put forward by PHT/Lincoln Technologies and by Phase Forward) -- specifically to assess the feasibility of developing an integrated, CDISC standard data and metadata model to support data acquisition. The resulting CDISC model is based on the Extensible Markup Language (XML), which is gaining wide acceptance as a general data interchange framework, and has been determined to be an effective approach to clinical data interchange. The goal of the CDISC XML Document Type Definition (DTD) Version 1.0 is to make available a first release of the definition of this CDISC model, in order to support sponsors, vendors and CROs in the design of systems and processes around a standard interchange format. 'The release of the CDISC Version 1.0 DTD provides the industry with a foundation of standards that will support unprecedented improvements in the quality and efficiency of future data interchange,' said Ken Harter, senior systems analyst, Amgen Inc. Both CDISC models can be reviewed at http://www.cdisc.org/publications.html. Comments are requested by January 31, 2001 and should be posted using the CDISC Web site Discussions option. CDISC is a non-profit organization with a mission to lead the development of standard, vendor-neutral, platform-independent data models that improve process efficiency while supporting the scientific nature of clinical research in the biopharmaceutical and healthcare industries."
"The overall goal of DTD 1.0 is to make available a first release of the definition of the CDISC DAS model, in order to support sponsors, vendors, and CROs in the design of systems and processes around a standard interchange format. The technical focus in the development of DTD 1.0 has been the definition of structures to represent the three major information components relating to a clinical trial: (1) clinical study metadata (item definitions and protocol); (2) clinical study administrative data (users and access privileges); (3) clinical study data (complete record of patient data and audit trail). This includes representation of metadata capable of supporting either direct electronic, or paper-based, data collection and capture of clinical data. Several longer-term objectives of the CDISC DAS data model are not fully supported in the DTD 1.0 version. These additional capabilities, which will be developed in later versions of the standard, include: (1) support for complex 'use case' interoperability between systems (e.g., incremental data interchange, two-way data interchange); (2) representation of queries and query resolution linked to clinical data; (3) support for long-term clinical data archive..."
[June 21, 1999] An announcement describes a Clinical Trial Data Model which is being submitted to the W3C in order to "accelerate Clinical Trial Data Exchange Standards." Phase Forward Incorporated has announced that it will be submitting its "established eXtensible Markup Language (XML)-based data model of their InForm Web-based clinical trial data collection and management software to key industry standards organizations to jumpstart the development of a data interchange model. The Phase Forward Document Type Definition (DTD) data model written in XML will be presented to the Clinical Data Interchange Standards Committee (CDISC), a special interest group of the Drug Information Association (DIA), at its meeting on June 28, 1999. Additionally, Phase Forward also has plans to submit its DTD to the Health Level 7 (HL7) organization and the World Wide Web Consortium (W3C). CDISC, HL7, and the W3C are the primary standards organizations focused on establishing a data model and XML-based Document Type Definition (DTD) for the healthcare informatics industries."